超声微泡在对比增强支气管内超声中的成像评估
本研究在体外和体内评估对比增强支气管内超声(CE-EBUS)系统(Olympus EU-ME2 PREMIER与BF-UC180F支气管镜)检测实验室合成微泡的能力,并与临床CEUS(Toshiba Aplio SSA-790A)和临床前CEUS(VisualSonics Vevo 2100)系统比较。结果显示CE-EBUS体外对比组织比(CTR)为28.9 ± 4.5 dB,与临床CEUS的29.7 ± 2.6 dB相似(p < 0.05);体内灌注曲线与临床前CEUS高度相关(Pearson相关系数 = 0.927,p < 0.05),且CTR为临床前超声系统的2.7倍。作者认为CE-EBUS可进行与商用临床前和临床超声系统相当的对比成像,可能有助于肺癌患者纵隔淋巴结的临床表征。
要点
- CE-EBUS体外CTR为28.9 ± 4.5 dB,与临床CEUS的29.7 ± 2.6 dB相似(p < 0.05)。
- CE-EBUS体内灌注曲线与临床前CEUS高度相关(Pearson相关系数 = 0.927,p < 0.05)。
- CE-EBUS体内CTR为临床前超声系统的2.7倍。
核心结论
- CE-EBUS可进行与商用临床前和临床超声系统相当的对比成像,可能有助于肺癌患者纵隔淋巴结的临床表征。
研究设计与样本
- 体外研究使用琼脂流模体和参考组织评估CE-EBUS微泡成像;体内研究分别使用A549荷瘤无胸腺裸鼠和AE17-OVA荷瘤C57BL/6小鼠评估微泡可检测性和灌注。
诊断标准与关键数值
- CE-EBUS体外对比组织比(CTR)为28.9 ± 4.5 dB,临床CEUS为29.7 ± 2.6 dB(p < 0.05)。
- CE-EBUS体内灌注曲线与临床前CEUS的Pearson相关系数为0.927(p < 0.05)。
- CE-EBUS体内CTR为临床前超声系统的2.7倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Endobronchial ultrasound (EBUS) is commonly used to guide transbronchial needle biopsies for the staging of lymph nodes in non-small cell lung cancer patients. Although contrast-enhanced ultrasound (CEUS) and microbubbles (MBs) can improve the diagnostic accuracy in tumors, the ability of contrast-enhanced EBUS (CE-EBUS) to image MBs has not yet been comprehensively evaluated. In this study, we assessed the ability of a CE-EBUS system (Olympus EU-ME2 PREMIER and BF-UC180F bronchoscope) to detect laboratory-synthesized MBs in comparison to clinical (Toshiba Aplio SSA-790A) and pre-clinical (VisualSonics Vevo 2100) CEUS systems in vitro and in vivo, respectively.
METHODS: Agar flow phantoms and reference tissue were used to assess CE-EBUS MB imaging in vitro, and A549 tumor-bearing athymic nude and AE17-OVA tumor-bearing C57BL/6 mice were used to assess MB detectability and perfusion in vivo, respectively.
RESULTS: Results revealed that despite the lower sensitivity of CE-EBUS to MB concentration in comparison to clinical CEUS, CE-EBUS yielded a similar contrast-to-tissue ratio (CTR) in vitro of 28.9 ± 4.5 dB for CE-EBUS, compared with 29.7 ± 2.6 dB for clinical CEUS (p < 0.05). In vivo, CE-EBUS generated a perfusion curve highly correlated with that obtained with the pre-clinical CEUS system (Pearson correlation coefficient = 0.927, p < 0.05). Moreover, CE-EBUS yielded a CTR 2.7 times higher than that obtained with the pre-clinical ultrasound system.
CONCLUSION: These findings together suggest that CE-EBUS can perform contrast imaging comparable to that produced by commercial pre-clinical and clinical ultrasound systems, with potential for clinical characterization of mediastinal lymph nodes in lung cancer patients.
引用
- McGrath S, Shen YJ, Aragaki M, et al. Imaging Microbubbles With Contrast-Enhanced Endobronchial Ultrasound. Ultrasound Med Biol. 2023. PMID: 37813701. doi:10.1016/j.ultrasmedbio.2023.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。